<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="320655">
  <stage>Registered</stage>
  <submitdate>28/09/2009</submitdate>
  <approvaldate>12/10/2009</approvaldate>
  <actrnumber>ACTRN12609000891224</actrnumber>
  <trial_identification>
    <studytitle>Ascending single doses of a novel Interlukin (IL-1 ) agonist administered to healthy subjects.</studytitle>
    <scientifictitle>Phase 1 Randomized, Double-Blind, Placebo-Controlled Trial in Healthy Male Volunteers To Examine The Safety, Tolerability, And Pharmacokinetics Of HMPL-011 After A Single Dose</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Auto-immune inflammatory disease</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Autoimmune diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Ascending single doses of a novel IL-10 agonist administered to healthy subjects.
In the single ascending dose 8 subjects, will receive single oral dose of test medication (or placebo ) in a double-blind manner.
Doses will be:
Cohort 1: 10 mg 
Cohort 2: 50 mg
Cohort 3: 200 mg
Cohort 4: 400 mg
Cohort 5: 800 mg
The duration of each cohort is 2 days postdose, with a single dose administered on Day 1.</interventions>
    <comparator>The placebo is citric acid solution. Both the interventonal drug and the placebo are administered orally</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and tolerability of single doses of HMPL-011 at 10,50, 200, 400 and 800 mgs will be assessed on the basis of adverse events reported, blood pressure, heart rate, body temperature (oral), electrocardiograms(ECGs), clinical laboratory tests and physical examination.These methods used will be medical equipment and questionning.</outcome>
      <timepoint>Subjects will be continuously monitored for adverse events, blood pressure, heart rate, body temperature, electrocardiograms(ECGs), clinical laboratory tests and physical examination whilst on study.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the pharmacokinetic profile of HMPL-011 at 10, 50,200, 400 and 800 mgs by blood analysis</outcome>
      <timepoint>The pharmacokinetics of HMPL-011 will be measured at predetermined timepoints throughout the study.these time points are: pre-dose, 25 mins, 1, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hrs after administration of drug/placebo.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy male subjects having Body Mass Index(BMI) between 19 and 34 kg/m2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Any significant acute or chronic medical conditions. Subjects at risk of tuberculosis(TB). Evidence of organ dysfunction or any clinically significant deviation from normal.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>19/10/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>32</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hutchison MediPharma</primarysponsorname>
    <primarysponsoraddress>Building 4, 720 Cai Lun Road, Z.J. Hi-Tec Park Shanghai, China, 201203</primarysponsoraddress>
    <primarysponsorcountry>China</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Hutchison MediPharma</fundingname>
      <fundingaddress>Building 4, 720 Cai Lun Road, Z.J. Hi-Tec Park Shanghai, China, 201203</fundingaddress>
      <fundingcountry>China</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>2/09/2009</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Associate Professor Peter Hodsman</name>
      <address>Centre for Clinical Studies
5th Floor Burnet Tower, AMREP Precinct, 89 Commercial Road, Melbourne, Victoria, 3004</address>
      <phone>613 9076 8900</phone>
      <fax>61 3 9076 8911</fax>
      <email>contactus@centreforclinicalstudies.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mary Franich</name>
      <address>Centre for Clinical Studies
5th Floor Burnet Tower, AMREP Precinct, 89 Commercial Road, Melbourne, Victoria, 3004</address>
      <phone>1800 243 733</phone>
      <fax>61 3 9076 8911</fax>
      <email>contactus@centreforclinicalstudies.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sue Mason</name>
      <address>Centre for Clinical Studies
5th Floor Burnet Tower, AMREP Precinct, 89 Commercial Road, Melbourne, Victoria, 3004</address>
      <phone>613 9076 8900</phone>
      <fax>61 3 9076 8911</fax>
      <email>s.mason@nucleusnetwork.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>